Axentis Pharma AG is a Swiss-based pharmaceutical company focused on value-added anti-infectives in combination with novel inhalation devices. Following
the entrance of a License Agreement with a Japanese partner, Axentis Pharma engaged in the development of AX-TOBRA,
a liposome-based drug-device combination to combat chronic lung diseases and respiratory disorders, especially cystic fibrosis. AX-TOBRA received Orphan Designations from EU-EMA and US-FDA.
To protect Axentis Pharma against loss and damage from malversations caused by its Japanese partner, Axentis Pharma initiated arbitration proceedings in Tokyo, and, ultimately, won a final and binding Arbitration Award against its former partner. The award was issued by the Japan Commercial Arbitration Association (JCAA) in Tokyo in August 2013. Currently, Axentis Pharma is seeking to enforce the Arbitration Award through judicial remedies.